Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 60/100

Failure Rate

11.1%

1 terminated/withdrawn out of 9 trials

Success Rate

75.0%

-11.5% vs industry average

Late-Stage Pipeline

11%

1 trials in Phase 3/4

Results Transparency

33%

1 of 3 completed trials have results

Key Signals

3 recruiting1 with results

Enrollment Performance

Analytics

Phase 2

6(66.7%)

Phase 1

2(22.2%)

Phase 3

1(11.1%)

9Total

Phase 2(6)

Phase 1(2)

Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (9)

Showing 9 of 9 trials

NCT05077709Phase 2Completed

IO102-IO103 in Combination With Pembrolizumab as First-line Treatment for Patients With Metastatic NSCLC, SCCHN, or mUBC

Role: lead

NCT05843448Phase 1Recruiting

IDO and PD-L1 Peptide Based Immune-Modulatory Therapeutic (IO102-IO103) in Combination With Pembrolizumab for BCG-Unresponsive or Intolerant, Non-Muscle Invasive Bladder Cancer

Role: collaborator

NCT05977907Phase 2Recruiting

Neoadjuvant Pembrolizumab and IO102-103 for Squamous Cell Carcinoma of the Head and Neck (SCCHN).

Role: collaborator

NCT05912244Phase 2Active Not Recruiting

A Study of IO102/IO103, Nivolumab, and Relatlimab in People With Melanoma

Role: collaborator

NCT05155254Phase 3Active Not Recruiting

IO102-IO103 in Combination With Pembrolizumab Versus Pembrolizumab Alone in Advanced Melanoma (IOB-013 / KN-D18)

Role: lead

NCT05280314Phase 2Recruiting

Phase II Trial of Neoadjuvant and Adjuvant IO102-IO103 and Pembrolizumab KEYTRUDA® in Patients With Resectable Tumors

Role: lead

NCT03562871Phase 1Completed

IO102 With Pembrolizumab, With or Without Chemotherapy, as First-line Treatment of Metastatic NSCLC

Role: lead

NCT03850522Phase 2Terminated

PD-L1 Peptide Vaccination in High Risk Smoldering Multiple Myeloma

Role: collaborator

NCT03939234Phase 2Completed

Peptide Vaccination With PD-L1 and PD-L2 Peptides in Untreated Chronic Lymphatic Leukemia.

Role: collaborator

All 9 trials loaded